New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma

References

• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–1821.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol: off J Am Soc Clin Oncol. 2012;30(18):2183–2189.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase ii study. J Clin Oncol: off J Am Soc Clin Oncol. 2012;30(18):2190–2196.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862.
   PubMed Web of Science ®Google Scholar
• Merli M, Ferrario A, Maffioli M, et al. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin’s lymphoma. Expert Opin Investig Drugs. 2015;24(7):897–912.
   PubMed Web of Science ®Google Scholar
• Merli M, Ferrario A, Basilico C, et al. Novel agents in indolent lymphomas. Ther Adv Hematol. 2013;4(2):133–148.
   PubMedGoogle Scholar
• Borate U, Mehta A, Reddy V, et al. Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin. Leuk Res. 2016;44:25–31.
   PubMed Web of Science ®Google Scholar
• Holm MP, Hjorthaug K, Baerentzen S, et al. Unsustained response to brentuximab as single agent therapy in a patient with CD30 positive angiosarcoma. Acta Oncol (Madr). 2016;55(2):251–253.
   PubMed Web of Science ®Google Scholar
• Kumar A, Younes A. Role of CD30 targeting in malignant lymphoma. Curr Treat Options Oncol. 2014;15(2):210–225.
   PubMed Web of Science ®Google Scholar
• Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96(13):4307–4312.
   PubMed Web of Science ®Google Scholar
• Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res: off J Am Assoc Cancer Res. 2011;17(20):6428–6436.
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–1465.
   PubMed Web of Science ®Google Scholar
• Fromm JR, McEarchern JA, Kennedy D, et al. Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin Lymphoma Myeloma Leuk. 2012;12(4):280–283.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res: off J Am Assoc Cancer Res. 2012;18(1):248–255.
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival data demonstrating durable responses from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;126(23):2736–2736.
   Web of Science ®Google Scholar
• Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236–1243.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7(1):24.
   Web of Science ®Google Scholar
• Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379–6381.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560–568.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schoder H, Yahalom J, et al. Pet-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284–292.
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer J, Martin P, et al. Post transplant outcome of a multicenter phase II study of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. Blood. 2015;126(23):519–519.
   Web of Science ®Google Scholar
• LaCasce AS, Bociek G, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;126(23):3982–3982.
   Web of Science ®Google Scholar
• Garcia-Sanz R, Sureda A, Alonso-Alvarez S, et al. Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish group of lymphoma and bone marrow transplantation (GELTAMO). Blood. 2015;126(23):582–582.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Cantonetti M, et al. Brentuximab vedotin in transplant-naive relapsed/refractory Hodgkin lymphoma: experience in 30 patients. Oncologist. 2015;20(12):1413–1416.
   PubMed Web of Science ®Google Scholar
• Michallet AS, Guillermin Y, Deau B, et al. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. Haematologica. 2015;100(7):e269–271.
   PubMed Web of Science ®Google Scholar
• Sawas A, Connors JM, Kuruvilla JG, et al. The combination of brentuximab vedotin (bv) and bendamustine (b) demonstrates marked activity in heavily treated patients with relapsed or refractory Hodgkin lymphoma (HL) and anaplastic large T-cell lymphoma (ALCL): results of an international multi cen…. Blood. 2015;126(23):586–586.
   Web of Science ®Google Scholar
• Diefenbach CS, Hong F, Cohen JB, et al. Preliminary safety and efficacy of the combination of brentuximab vedotin and ipilimumab in relapsed/refractory Hodgkin lymphoma: a trial of the ecog-acrin cancer research group (e4412). Blood. 2015;126(23):585–585.
   Web of Science ®Google Scholar
• Zinzani PL, Viviani S, Anastasia A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 2013;98(8):1232–1236.
   PubMed Web of Science ®Google Scholar
• Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin study group experience. Blood. 2012;120(7):1470–1472.
   PubMed Web of Science ®Google Scholar
• Sweetenham J, Walewski J, Nademanee AP, et al. Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse. Blood. 2015;126(23):3172–3172.
   Google Scholar
• Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica. 2012;97(7):1073–1079.
   PubMed Web of Science ®Google Scholar
• De Filippi R, Cillo M, Crisci S, et al. Continuous exposure to bendamustine (BDM) results in stable upregulation of CD30 and increased sensitivity to brentuximab vedotin (BV) in tumor cells of Hodgkin lymphoma (HL). Blood. 2015;126(23):2479–2479.
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–1356.
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Pellegrini C, et al. Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase ii study. Haematologica. 2016;101(4):e139–141.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Arnason JE, LaCasce AS, et al. Brentuximab vedotin plus AVD for non-bulky limited stage classical Hodgkin lymphoma: a phase 2 trial [ICML abstract 087]. Hematol Oncol. 2015;33(suppl 1):146.
   Google Scholar
• Kumar A, Yahalom J, Schoder H, et al. Preliminary efficacy and safety of brentuximab vedotin and AVD chemotherapy followed by involved-site radiotherapy in early stage, unfavourable risk Hodgkin lymphoma [ICML abstract 088]. Hematol Oncol. 2015;33(suppl 1):147.
   Google Scholar
• Borchmann P, Eichenauer DA, Pluetschow A, et al. Targeted BEACOPP variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: final analysis of a randomized phase II study. Blood. 2015;126(23):580–580.
   Web of Science ®Google Scholar
• Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798–2804.
   PubMed Web of Science ®Google Scholar
• Evens AM, Hamlin P, Nabhan C, et al. Sequential brentuximab vedotin and AVD for older Hodgkin lymphoma patients: initial results from a phase 2 multicentre study [ICML abstract 089]. Hematol Oncol. 2015;33(suppl 1):147.
   Google Scholar
• Yasenchak CA, Forero-Torres A, Cline-Burkhardt VJM, et al. Brentuximab vedotin in combination with dacarbazine or bendamustine for frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim results of a multi-cohort phase 2 study. Blood. 2015;126(23):587–587.
   Web of Science ®Google Scholar
• Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the hd12 trial of the German Hodgkin study group. J Clin Oncol: off J Am Soc Clin Oncol. 2011;29(32):4234–4242.
   PubMed Web of Science ®Google Scholar
• Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692–695.
   PubMed Web of Science ®Google Scholar
• Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and stanford v in older Hodgkin lymphoma patients: a comprehensive analysis from the north American intergroup trial e2496. Br J Haematol. 2013;161(1):76–86.
   PubMed Web of Science ®Google Scholar
• Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179–184.
   PubMed Web of Science ®Google Scholar
• Han TH, Gopal AK, Ramchandren R, et al. O’Connor OA: Cyp3a-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol. 2013;53(8):866–877.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Four-year survival data from an ongoing pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2014;124(21):3095–3095.
   Web of Science ®Google Scholar
• Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983–2986.
   PubMed Web of Science ®Google Scholar
• Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81–82.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–3100.
   PubMed Web of Science ®Google Scholar
• Lamarque M, Bossard C, Contejean A, et al. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica. 2016;101(3):e103–106.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137–3143.
   PubMed Web of Science ®Google Scholar
• d’Amore F, Leppa S, Da Silva MG, et al. First interim efficacy and safety analysis of an international phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with chemotherapy with or without alemtuzumab and consolidated by high dose therapy. ASH Annu Meet Abstr. 2012;120(21):57.
   Google Scholar
• Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Reimer P, Rüdiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106–113.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Shustov AR, Forero-Torres A, et al. Frontline treatment of CD30+ peripheral T-cell lymphomas with brentuximab vedotin in combination with chp: 3-year durability and survival follow-up. Blood. 2015;126(23):1537–1537.
   Web of Science ®Google Scholar
• Duvic M. CD30+ neoplasms of the skin. Curr Hematol Malig Rep. 2011;6(4):245–250.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Knobler R, Willemze R, et al. Eortc consensus recommendations for the treatment of mycosis fungoides/sezary syndrome. Eur J Cancer. 2006;42(8):1014–1030.
   PubMed Web of Science ®Google Scholar
• Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–4035.
   PubMed Web of Science ®Google Scholar
• Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–3765.
   PubMed Web of Science ®Google Scholar
• Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–3758.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL rituximab-chop consortium program study. Blood. 2013;121(14):2715–2724.
   PubMed Web of Science ®Google Scholar
• Slack GW, Steidl C, Sehn LH, et al. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Br J Haematol. 2014;167(5):608–617.
   PubMed Web of Science ®Google Scholar
• Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–1402.
   PubMed Web of Science ®Google Scholar
• Ward JP, Thein J, Luo J, et al. A phase I trial of brentuximab vedotin in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood. 2015;126(23):3988–3988.
   Google Scholar
• Yasenchak CA, Halwani A, Advani R, et al. Brentuximab vedotin with RCHOP as frontline therapy in patients with high-intermediate/high-risk diffuse large B cell lymphoma (DLBCL): results from an ongoing phase 2 study. Blood. 2015;126(23):814–814.
   Web of Science ®Google Scholar
• Svoboda J, Strelec LE, Nasta SD, et al. Brentuximab vedotin in combination with multi-agent chemotherapy is well tolerated and shows promising activity as frontline treatment for primary mediastinal B-cell lymphoma. Blood. 2015;126(23):2694–2694.
   Web of Science ®Google Scholar
• Pfeifer M, Zheng B, Erdmann T, et al. Anti-CD22 and anti-CD79b antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29(7):1578–1586.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79b antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704–715.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Iw F, Sehn LH, et al. A phase I study of the anti-CD79b antibody-drug conjugate (ADC) dcds4501a targeting CD79b in relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). ASH Annu Meet Abstr. 2012;120(21):56.
   Google Scholar
• Chen AI, Lebovic D, Brunvand MW, et al. Final results of a phase I study of the anti-CD22 antibody-drug conjugate (ADC) dcdt2980s with or without rituximab (rtx) in patients (pts) with relapsed or refractory (r/r) b-cell non-Hodgkin’s lymphoma (NHL). ASH Annu Meet Abstract. 2013;122(Abs):4399.
   Google Scholar
• Morschhauser F, Flinn I, Advani RH, et al. Updated results of a phase II randomized study (romulus) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma. ASH Annu Meet Abstract. 2014;124(Abs):4457.
   Google Scholar
• Advani RH, Flinn I, Sharman JP, et al. Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): durable responses at lower dose level. J Clin Oncol (ASCO Annual Meeting) 2015;33(Suppl):abstr 8503.
   Google Scholar
• Bartlett NL, Chen AI, Kolibaba KS, et al. Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): preliminary results of a phase Ib dose-escalation. Blood. 2015;126(23):2726–2726.
   Web of Science ®Google Scholar
• Ogura M, Tobinai K, Hatake K, et al. Phase I study of inotuzumab ozogamicin (cmc-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8):1840–1845.
   PubMed Web of Science ®Google Scholar
• Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–583.
   PubMed Web of Science ®Google Scholar
• Goy A, Forero A, Wagner-Johnston N, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016. doi:10.1111/bjh.14094. [Epub ahead of print].
   Web of Science ®Google Scholar
• Ogura M, Tobinai K, Hatake K, et al. Phase 1 study of inotuzumab ozogamicin combined with r-cvp for relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. Clin Cancer Res: off J Am Assoc Cancer Res. 2016. pii: clincanres.2488.2015. [Epub ahead of print].
   Google Scholar
• Younes A, Kim S, Romaguera J, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate sar3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol: off J Am Soc Clin Oncol. 2012;30(22):2776–2782.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Dupuis J, Tilly H, et al. A dose-escalation study of sar3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res: off J Am Assoc Cancer Res. 2014;20(1):213–220.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, De Guibert S, et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (sar3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol. 2016;173(5):722–730.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Forero-Torres A, Shah BD, et al. Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-CD19a in relapsed or refractory b-lineage non-Hodgkin lymphoma. ASH Annu Meet Abstract. 2014;124(Abs):1741.
   Google Scholar
• Moskowitz CH, Fanale MA, Shah BD, et al. A phase 1 study of denintuzumab mafodotin (SGN-CD19a) in relapsed/refactory b-lineage non-Hodgkin lymphoma. Blood. 2015;126(23):182–182.
   Web of Science ®Google Scholar
• Ryan MC, Schimpf B, Anderson M, et al. SGN-CD19b, a pyrrolobenzodiazepine (pbd)-based anti-CD19 drug conjugate, demonstrates potent preclinical activity against B-cell malignancies. Blood. 2015;126(23):594–594.
   Web of Science ®Google Scholar
• Zammarchi F, Williams DG, Adams L, et al. Pre-clinical development of adct-402, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate (ADC) targeting CD19-expressing B-cell malignancies. Blood. 2015;126(23):1564–1564.
   Web of Science ®Google Scholar
• Deckert J, Ponte JF, Coccia JA, et al. Preclinical mechanistic studies investigating neutrophil and lymphoid cell depletion by imgn529, a CD37-targeting antibody-drug conjugate (ADC). Blood. 2014;124(21):3119–3119.
   Web of Science ®Google Scholar
• Sawas A, Savage KJ, Perez R, et al. A phase 1 study of the anti-CD37 antibody-drug conjugate ags67e in advanced lymphoid malignancies. Interim results. Blood. 2015;126(23):3976–3976.
   Web of Science ®Google Scholar